Bottom line
PBE vs GNOM: the short answer
PBE (Invesco Biotechnology & Genome ETF) and GNOM (Global X Genomics & Biotechnology ETF) are quite different portfolios: only about 22% of their top holdings (by weight) are shared.
GNOM is cheaper at 0.5% vs 0.59% — a difference of $9.00 a year per $10,000 invested.
Over five years, PBE returned +3.4% a year vs −13.3% for GNOM.
Updated Nov 19, 2026
PBE vs GNOM side by side
| PBE | GNOM | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | Invesco | Global X |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.59% | 0.5% |
| Annual cost per $10k | $59 | $50 |
| 10-yr cost on $10k (prospectus) | $738 | $628 |
| Max front load | None | None |
| 12b-1 fee | — | 0% |
| 1-yr return | +24.7% | +19.0% |
| 5-yr return (annualized) | +3.4% | −13.3% |
| 10-yr return (annualized) | +5.2% | — |
| Best quarter | +25.3% | +38.8% |
| Worst quarter | −24.3% | −24.2% |
| Net assets (fund) | $281.9M | $55.8M |
| Number of holdings | 33 | 51 |
| Portfolio turnover | 103% | 34% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PBE | GNOM | Difference |
|---|---|---|---|
| 2025 | +24.7% | +19.0% | +5.7% |
| 2024 | +1.1% | −16.2% | +17.3% |
| 2023 | +3.7% | −8.6% | +12.3% |
| 2022 | −10.8% | −36.1% | +25.3% |
| 2021 | +1.6% | −16.0% | +17.5% |
| 2020 | +25.5% | +51.6% | −26.1% |
Source: Fund prospectus bar charts
Holdings overlap
7 of PBE's top 25 holdings also appear in GNOM's top 25.
| Holding | PBE | GNOM |
|---|---|---|
| Vertex Pharmaceuticals Inc. | 4.99% | 3.95% |
| Gilead Sciences, Inc. | 4.43% | 1.95% |
| Bio-Techne Corp. | 3.73% | 3.41% |
| Illumina, Inc. | 3.51% | 4.82% |
| Qiagen N.V. | 2.89% | 3.54% |
| BioMarin Pharmaceutical Inc. | 2.82% | 4.09% |
| Veracyte, Inc. | 2.60% | 3.64% |
Source: SEC Form N-PORT
PBE top 10
- Invesco Private Prime Fund — 12.89%
- Regeneron Pharmaceuticals, Inc. — 5.47%
- Amgen Inc. — 5.22%
- CareDx, Inc. — 5.04%
- Vertex Pharmaceuticals Inc. — 4.99%
- Invesco Private Government Fund — 4.97%
- Royalty Pharma PLC — 4.94%
- Biogen Inc. — 4.79%
- Gilead Sciences, Inc. — 4.43%
- United Therapeutics Corp. — 4.08%
GNOM top 10
- Guardant Health, Inc. — 5.59%
- Illumina, Inc. — 4.82%
- Natera, Inc. — 4.15%
- Biomarin Pharmaceutical Inc. — 4.09%
- Arrowhead Pharmaceuticals, Inc. — 4.07%
- Legend Biotech Corp — 4.05%
- Praxis Precision Medicines Inc — 4.01%
- Twist Bioscience Corp — 3.97%
- Vertex Pharmaceuticals Incorporated — 3.95%
- CRISPR Therapeutics AG — 3.85%
FAQ
What is the difference between PBE and GNOM?
Which is cheaper, PBE or GNOM?
Should I own both PBE and GNOM?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.